Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 10/16/2024 | $22.00 | Outperform → Strong Buy | Raymond James |
| 9/27/2024 | $10.00 → $13.00 | Overweight | JP Morgan |
| 9/19/2024 | $11.00 | Buy | B. Riley Securities |
| 9/9/2024 | $10.00 | Overweight | JP Morgan |
| 5/15/2024 | $11.00 | Overweight | Wells Fargo |
| 12/19/2023 | $5.00 → $12.00 | Market Perform → Outperform | Leerink Partners |
| 7/5/2023 | $7.00 | Outperform | Raymond James |
| 5/24/2023 | $7.00 → $5.00 | Buy → Hold | Jefferies |
8-K - Wave Life Sciences Ltd. (0001631574) (Filer)
S-8 - Wave Life Sciences Ltd. (0001631574) (Filer)
S-3ASR - Wave Life Sciences Ltd. (0001631574) (Filer)
CAMBRIDGE, Mass., Nov. 15, 2024 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (NASDAQ:WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, today announced that Paul Bolno, MD, MBA, President and Chief Executive Officer, is scheduled to participate in an analyst-led fireside chat at the Jefferies London Healthcare Conference on Wednesday, November 20, 2024, at 4:30 p.m. GMT / 11:30 a.m. ET. A live webcast of this presentation can be accessed by visiting "Investor Events" on the Investor Relations section of the Wave Life Sciences website: https://ir.wavelifesciences.com/events-publications/events. A replay of this
Achieved first-ever RNA editing in humans in RestorAATion-2 trial of WVE-006 (GalNAc-AIMer) in alpha-1 antitrypsin deficiency and announced three wholly owned GalNAc-AIMer preclinical programs that offer first-in-class approaches to address unmet needs in cardiometabolic diseases WVE-007 (INHBE GalNAc-siRNA) clinical trial on track for 1Q 2025; preclinical data demonstrates opportunities for monotherapy, for synergistic use with GLP-1s, and for maintenance to avoid rebound weight gain following cessation of GLP-1s Received supportive initial feedback from FDA on WVE-003; FDA is engaged in discussing pathways to accelerated approval and open to Wave's plan to evaluate biomarkers, in
CAMBRIDGE, Mass., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (NASDAQ:WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, will host a live webcast and conference call at 8:30 a.m. ET on Tuesday, November 12, 2024, to review the company's third quarter 2024 financial results and provide business updates. The webcast and conference call may be accessed by visiting "Investor Events" on the investors section of the Wave Life Sciences website: https://ir.wavelifesciences.com/events-publications/events. Analysts planning to participate during the Q&A portion of the live call can join the conference
SC 13G/A - Wave Life Sciences Ltd. (0001631574) (Subject)
SC 13G/A - Wave Life Sciences Ltd. (0001631574) (Subject)
SC 13D/A - Wave Life Sciences Ltd. (0001631574) (Subject)
During the last three months, 4 analysts shared their evaluations of WAVE Life Sciences (NASDAQ:WVE), revealing diverse outlooks from bullish to bearish. The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 2 2 0 0 0 Last 30D 1 0 0 0 0 1M Ago 0 1 0 0 0 2M Ago 0 1 0 0 0 3M Ago 1 0 0 0 0 Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $15.5, a high estimate of $19.00, and a low estimate of $11.00. Observing a dow
HC Wainwright & Co. analyst Andrew Fein reiterates WAVE Life Sciences (NASDAQ:WVE) with a Buy and maintains $15 price target.
U.S. stock futures were mixed this morning, with the Nasdaq futures gaining around 0.2% on Wednesday. Shares of Worthington Enterprises, Inc. (NYSE:WOR) fell sharply in today's pre-market trading after the company posted downbeat quarterly results. Worthington Industries posted adjusted earnings of 74 cents per share, missing analysts' estimates of 94 cents per share. The company posted quarterly sales of $318.801 million versus estimates of $359.390 million, according to data from Benzinga Pro. Worthington shares dipped 7.5% to $46.38 in pre-market trading. Here are some big stocks recording losses in today's pre-market trading session. Taysha Gene Therapies, Inc. (NASDAQ:TS
Achieved first-ever RNA editing in humans in RestorAATion-2 trial of WVE-006 (GalNAc-AIMer) in alpha-1 antitrypsin deficiency and announced three wholly owned GalNAc-AIMer preclinical programs that offer first-in-class approaches to address unmet needs in cardiometabolic diseases WVE-007 (INHBE GalNAc-siRNA) clinical trial on track for 1Q 2025; preclinical data demonstrates opportunities for monotherapy, for synergistic use with GLP-1s, and for maintenance to avoid rebound weight gain following cessation of GLP-1s Received supportive initial feedback from FDA on WVE-003; FDA is engaged in discussing pathways to accelerated approval and open to Wave's plan to evaluate biomarkers, in
CAMBRIDGE, Mass., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (NASDAQ:WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, will host a live webcast and conference call at 8:30 a.m. ET on Tuesday, November 12, 2024, to review the company's third quarter 2024 financial results and provide business updates. The webcast and conference call may be accessed by visiting "Investor Events" on the investors section of the Wave Life Sciences website: https://ir.wavelifesciences.com/events-publications/events. Analysts planning to participate during the Q&A portion of the live call can join the conference
Mean muscle content-adjusted dystrophin expression of 9.0% and unadjusted dystrophin of 5.5%, with high consistency across participants, in a prespecified analysis; dystrophin was comprised of two isoforms consistent with Becker muscular dystrophy patients who display milder disease Data demonstrated meaningful improvement in serum biomarkers for muscle health, with localization of WVE-N531 in myogenic stem cells and regeneration of myofibers Skeletal muscle concentrations of ~41,000 ng/g combined with 61-day tissue half-life support monthly dosing going forward; preclinical data suggest participants may have even higher concentrations in heart and diaphragm WVE-N531 was safe and well tol
4 - Wave Life Sciences Ltd. (0001631574) (Issuer)
4 - Wave Life Sciences Ltd. (0001631574) (Issuer)
4 - Wave Life Sciences Ltd. (0001631574) (Issuer)
Raymond James upgraded Wave Life Sciences from Outperform to Strong Buy and set a new price target of $22.00
JP Morgan resumed coverage of Wave Life Sciences with a rating of Overweight and set a new price target of $13.00 from $10.00 previously
B. Riley Securities initiated coverage of Wave Life Sciences with a rating of Buy and set a new price target of $11.00
4 - Wave Life Sciences Ltd. (0001631574) (Issuer)
4 - Wave Life Sciences Ltd. (0001631574) (Issuer)
4/A - Wave Life Sciences Ltd. (0001631574) (Issuer)
CAMBRIDGE, Mass., May 09, 2024 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (NASDAQ:WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, today announced the appointment of Erik Ingelsson, MD, PhD, as Chief Scientific Officer. Dr. Ingelsson will drive Wave's emerging therapeutic portfolio strategy, including growing its genetics and genomics capabilities for identifying new, high impact targets, and leveraging the company's best-in-class multimodal discovery and development platform to advance transformative RNA medicines. Most recently, Dr. Ingelsson served as Senior Vice President, Head of Target Discovery, at GSK
BOTHELL, Wash., March 21, 2022 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ:ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today announced the appointment of Michael A. Panzara, M.D., MPH to its Board of Directors. Dr. Panzara currently serves as Chief Medical Officer, Head of Therapeutics Discovery and Development at Wave Life Sciences (NASDAQ:WVE) and brings over 20 years of biopharmaceutical industry experience developing therapies for neurological disorders, including in leadership roles at Sanofi Genzyme and Biogen. "Mike is a recognized and experienced leader in the development
CAMBRIDGE, Mass., Dec. 02, 2020 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, announced today that Jonathan Rosin has been appointed as Chief Human Resources Officer (CHRO). As CHRO, Mr. Rosin will provide strategic enterprise counsel and leadership, both as a member of Wave’s Executive Team and by leading the human resources function. “Jonathan is an accomplished leader with the breadth of human resources experience necessary to help guide Wave as we prepare to support five programs in clinical trials in 2021, as well as advance a robust precl